The global saliva collection and diagnostics market size is estimated to reach USD 1.10 billion by 2030, registering a CAGR of 4.7% from 2025 to 2030. Owing to the increasing prevalence of communicable and non-communicable diseases along with the increasing preference for non-invasive methods for disease diagnosis. Moreover, the growing need to diagnose COVID-19-infected symptomatic and asymptomatic patients have created significant opportunities for the market. In August 2022, a research study published in PLOS ONE stated that oral fluid samples could be used for various diagnostic assays, such as COVID-19, due to its storage and ease of sample collection. Moreover, researchers have also stated that even if the salivary samples were stored for more than 28 days, it would remain reliable and useful.
Furthermore, the global burden of cancer and related deaths rose in 2020, majorly because of the increasing aging population and socioeconomic development. In April 2020, an article published in the American Society of clinical oncology stated that more than 50% of cancers globally are diagnosed in people aged 65 and older. Therefore, the saliva-based test is considered to be the best non-invasive procedure to detect cancer. In August 2022, OrisDX announced of developing a saliva-based non-invasive molecular test to diagnose and detect oral cancer at an early stage which would help in improving patient outcomes.
There has been significant growth in the adoption of saliva samples for both clinical and research applications as it offers non-invasive sampling, easy, simple collection, and higher patient compliance, among others. Several advancements and developments are happening in saliva specimens which would advance the proteomics field. For instance, in September 2022, an article published in India Today stated that researchers from IIT Roorkee identified salivary proteins which could help in predicting metastatic triple-negative breast cancer.
Key players operating in the market are taking several initiatives such as entering into strategic alliances and launching new products which are contributing to the overall growth. For instance, in January 2021, OraSure Technologies, Inc. announced that its saliva collection device, OMNIgene·ORAL, has been selected by Chronomics Limited for the SARS CoV-2 PCR test. Similarly, in August 2020, Fluidigm Corporation announced receiving FDA authorization for its saliva-based test, Advanta Dx SARS-CoV-2 RT-PCR assay. This test would help to detect the presence of coronavirus in the sample.
This product will be delivered within 1-3 business days.
Furthermore, the global burden of cancer and related deaths rose in 2020, majorly because of the increasing aging population and socioeconomic development. In April 2020, an article published in the American Society of clinical oncology stated that more than 50% of cancers globally are diagnosed in people aged 65 and older. Therefore, the saliva-based test is considered to be the best non-invasive procedure to detect cancer. In August 2022, OrisDX announced of developing a saliva-based non-invasive molecular test to diagnose and detect oral cancer at an early stage which would help in improving patient outcomes.
There has been significant growth in the adoption of saliva samples for both clinical and research applications as it offers non-invasive sampling, easy, simple collection, and higher patient compliance, among others. Several advancements and developments are happening in saliva specimens which would advance the proteomics field. For instance, in September 2022, an article published in India Today stated that researchers from IIT Roorkee identified salivary proteins which could help in predicting metastatic triple-negative breast cancer.
Key players operating in the market are taking several initiatives such as entering into strategic alliances and launching new products which are contributing to the overall growth. For instance, in January 2021, OraSure Technologies, Inc. announced that its saliva collection device, OMNIgene·ORAL, has been selected by Chronomics Limited for the SARS CoV-2 PCR test. Similarly, in August 2020, Fluidigm Corporation announced receiving FDA authorization for its saliva-based test, Advanta Dx SARS-CoV-2 RT-PCR assay. This test would help to detect the presence of coronavirus in the sample.
Saliva Collection And Diagnostics Market Report Highlights
- The growth of the overall saliva collection and diagnostics market is attributed to the increasing prevalence of infectious diseases along with the growing demand for non-invasive methods for disease detection
- By site of collection, the submandibular/sublingual gland collection segment dominated the market in 2024, owing to the increasing cases of sialoliths among the young population
- By application, the disease diagnostics segment dominated the market in 2024 owing to the increasing aging population globally coupled with increasing cases of diseases such as cancer, cardiovascular diseases, and others
- By end use, the diagnostic laboratories segment captured the highest market share in 2024, owing to the growing number of diagnostic labs along with the introduction of advanced technology which could help in the early detection of diseases
- By region, North America dominated the market in 2024 owing to the presence of several market players along with increasing support from the government to boost the demand in the region.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Saliva Collection and Diagnostics Market Variables, Trends & Scope
Chapter 4. Saliva Collection and Diagnostics Market: Site of Collection Estimates & Trend Analysis
Chapter 5. Saliva Collection and Diagnostics Market: Application Estimates & Trend Analysis
Chapter 6. Saliva Collection and Diagnostics Market: End-Use Estimates & Trend Analysis
Chapter 7. Saliva Collection and Diagnostics Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Neogen Corporation
- Abbott
- Sarstedt AG & Co.KG
- Autogen, Inc.
- Oasis Diagnostics
- Porex
- Salimetrics, LLC
- Takara Bio, Inc.
- Arcis Bio
- Orasure Technologies
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | November 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 0.82 Billion |
| Forecasted Market Value ( USD | $ 1.1 Billion |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
